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Abstract
Many microbial and plant-derived metabolites contribute to the production of inflammatory mediators and the
expression of pro-inflammatory molecules. Ophiobolin A (OPA) is a fungal secondary metabolite produced by
Bipolaris species. The aim of our study was to examine the acute effects of this compound on inflammatory
processes.
Male Wistar rats were treated with 5% ethanol, 0.01 mg/kg OPA, 0.1 mg/kg OPA and 1.0 mg/kg OPA per os.
After 24 h of the administrations, inflammatory mediators such as interleukin-6 (IL-6), tumour necrosis factor-
alpha (TNF-a) and myeloperoxidase (MPO) enzyme as well as heme oxygenase (HO) activity were measured in
both plasma and cardiac tissue, along with serum alanine aminotransferase (ALT) and aspartate aminotransfer-
ase (AST).We found that OPA caused a significant elevation in the concentrations of IL-6 and TNF-a, increased
MPO activity and decreased HO enzyme activity in the plasma. While OPA induces inflammation in the plasma,
it did not change the level of inflammatory mediators in the cardiac tissue and the concentrations of serum ALT
and AST. Our findings indicate that rapid release of inflammatory mediators by OPA promotes systemic
inflammation. However, this acute OPA treatment does not show toxic effects on the cardiac tissue and the
concentrations of liver enzymes.
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Introduction
Inflammation is a complex set of interactions among
soluble factors (cytokines) and cells that can arise in
both tissue and plasma in response to infectious, toxic
or traumatic injury.1,2 The pro-inflammatory cyto-
kines, such as tumour necrosis factor-alpha (TNF-a),
interleukin-1-beta (IL-1) and IL-6, are involved in
the initiation and amplification of the inflammatory
process. TNF-a and IL-1 act in synergy to enhance
IL-6 secretion and may significantly contribute to the
overall systemic inflammation.3 Along with the
effects of cytokines, myeloperoxidase (MPO) activ-
ity, which synthesized and secreted by neutrophils, is
determined as an inflammatory biomarker. The
plasma or tissue concentrations of MPO are markers
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of the neutrophil proliferation/infiltration and severity
of inflammation.4
It has been reported that heme oxygenase (HO)
plays a central role in oxidative stress and inflamma-
tory processes. The upregulation of the HO enzyme
pathway has significant antioxidant and anti-
inflammatory effects in both the circulation and tissue
injury. HO enzyme system serves a vital metabolic
function as the rate-limiting step in the degradation
of heme to generate carbon monoxide (CO), iron and
biliverdin, which is converted to bilirubin. HO-1 end
products generated from heme degradation may mod-
ulate inflammation. Cumulative evidence suggests
that CO and bilirubin have anti-proliferative and
anti-inflammatory effects via downregulate the pro-
duction of pro-inflammatory cytokines (e.g. IL-6, IL-
1 and TNF-a) and upregulate the anti-inflammatory
cytokines (e.g. IL-10).5,6 The strong interaction
between HO enzyme and pro-inflammatory cytokines
(which play a pivotal role in pathological conditions)
can be major factors to promote systemic
inflammation.
Natural compounds, including plant and microbial
secondary metabolites, can directly influence the pro-
duction of inflammatory mediators as well as the
expression of transcription factors and key pro- or
anti-inflammatory molecules.7,8
Ophiobolins are sesterterpenoid-type secondary
metabolites, a group of pentaprenyl terpenoid com-
pounds whose structures are derivable from geranyl-
farnesyl diphosphate (C 25). They are characterized
by a unique structure of a tricyclic 5-8-5 ring system
derived from head to tail linkages of five isoprene
units. Ophiobolins are produced by some phytopatho-
genic fungi, mainly the members of the genus Bipo-
laris (Cochliobolus)9 and some species of the genera
Drechslera (Pyrenophora), Aspergillus (Emericella,
Neosartorya) and others.10 Ophiobolin A (OPA) was
the first member of the group to be isolated and char-
acterized in the mid-1960s.9 Ophiobolins are known
to be effective phytotoxins, and a large number of
studies have described the action of OPA in
plants.11,12 Their effect is less known in mammals,
though there are some studies also in this field, for
example, the biological effects of OPA on human
cancer cells13–15 and boar spermatozoa15 were
described.
In our present study, we aimed to characterize
OPA-mediated acute systemic changes on the inflam-
matory process. Thus, we tested the effect of different
doses (0.01, 0.1 and 1.0 mg/kg) of OPA on
inflammatory mediators (IL-6, TNF-a, MPO activity
and HO activity) in rat plasma. To clarify the potential
cytotoxic effects of OPA, we tested it on both cardiac
tissue and liver. The alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) markers were
measured to analyse the influence of OPA on
hepatotoxicity.
Methods
Animals and experimental design
All manipulations were performed in accordance with
the standards of the European Community guidelines
on the care and use of laboratory animals and had
been approved by the Institutional Ethics Committee
at the University of Szeged.
All the animals were housed in a temperature-
controlled facility (23C) maintained on a 12/12 h
of light/dark cycle with food and water provided ad
libitum.
Male Wistar rats (weight: 250–350 g; Toxi-Coop
Zrt., Dunakeszi, Hungary) were randomly divided
into four groups: 5% ethanol vehicle control (n ¼ 18),
0.01mg/kgOPA (n¼ 18), 0.1mg/kgOPA (n¼ 18) and
1.0 mg/kg OPA (n ¼ 18).
Twenty-four hours after vehicle (once, 1.0 mL of
5% ethanol, p.o.) or OPA (once, 0.01 mg/kg, 0.1 mg/
kg or 1.0 mg/kg in 1.0 mL of 5% ethanol, per os [p.o.])
treatment, the animals were killed and blood sample
as well as the cardiac left ventricle (LV) was collected
for analyses.
Measurement of plasma and cardiac
LV IL-6 and TNF-a concentrations
Plasma samples were centrifuged at 2000  gmax for
20 min at 4C. The cardiac LV samples were homo-
genized (Ultra-Turrax T25, IKA-Labortechnik, 2 
10 s on ice) in 2 mL modified Greenburger buffer
(300 mM sodium chloride, 15 mM TRIS, 2 mM mag-
nesium chloride (MgCl2), 2 mM Triton X-100, 0.2
mM phenylmethanesulfonyl fluoride, 100 ng/mL leu-
peptin, 100 ng/mL aprotinin, 10 mg/L trypsin inhibi-
tor and 100 ng/mL pepstatin-A). Tissue homogenates
were sonicated for 10 s and centrifuged at 15000  g
for 15 min. The plasma and cardiac IL-6 and TNF-a
levels were determined by means of quantitative
enzyme-linked immunosorbent assays (ELISA)
according to the manufacturer’s instructions (Quanti-
kine rat IL-6 and TNF-alpha Elisa kit; R&D Systems,
Minneapolis, Minnesota, USA). Optical density was
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measured at 450 nm (Benchmark Microplate Reader;
Bio-Rad, Budapest, Hungary). Plasma IL-6 and TNF-
a were expressed as pictogram per millilitre plasma
and cardiac values were defined as pictogram per
milligram protein.
Plasma and cardiac LV MPO activity
Plasma samples were centrifuged at 2000  gmax for
20 min at 4C. The cardiac LV tissues were homo-
genized twice for 30–30 s (Ultra Turrax T25, 13 500 r/
min) in ice-cold phosphate buffer (50 mM, pH 6.0),
freeze-thawed three times and then centrifuged
(15,000  g for 20 min at 4C). A 12-mL aliquot of
the plasma or cardiac supernatant was mixed with
280 mL of phosphate buffer (50 mM, pH 6) contain-
ing 0.167 mg/mL of O-dianisidine dihydrochloride,
and the reaction was started with 10 mL of 0.03%
hydrogen peroxide and assayed spectrophotometri-
cally at 490 nm (Benchmark Microplate Reader;
Bio-Rad) after 90 s of shaking. Plasma MPO activity
was expressed as milliunit per millilitre plasma and
cardiac values were expressed as milliunit per milli-
gram protein.
Plasma and cardiac LV HO activity
Plasma samples were centrifuged at 2000  g for 20
min at 4C. The cardiac LV tissues were homoge-
nized (Ultra Turrax T25; 13 500 r/min; 2  30 s) in
ice-cold 10 mM N-2-hydroxyethylpiperazine-2-
ethanesulfonic acid, 32 mM sucrose, 1 mM dithiotrei-
tol, 0.1 mM ethylene diaminetetraacetic acid diso-
dium salt dihydrate, 10 mg/mL trypsin inhibitor, 10
mg/mL leupeptin and 2 mg/mL aprotinin, at pH 7.4.
The cardiac supernatant was collected by centrifuga-
tion at 15,000  g for 20 min at 4C. The reaction
mixture contained the following components in a final
volume of 1.5 mL: 2 mM glucose-6-phosphate, 0.14
U/mL glucose-6-phosphate dehydrogenase, 15 mM
hemin, 120 mg/mL rat liver cytosol (as a source of
biliverdin reductase), 2 mM MgCl2  6 H2O, 100
mM KH2PO4 and 150 mL of plasma or cardiac LV
supernatant. To start the reaction, 100 mL reduced
form of nicotinamide adenine dinucleotide phosphate
(150 mM) was added to the samples and they were
then incubated in the dark at 37C for 60 min. The
reaction was stopped by placing the samples on ice.
The bilirubin formed was calculated from the differ-
ence between the optical densities obtained at 464 and
530 nm. Bilirubin solution was used as standard
(58.47 mg/mL; 10 mM). One unit of HO activity was
defined as the amount of bilirubin (nM) produced per
hour per millilitre plasma or the amount of bilirubin
(nM) produced hour per milligram protein.
Determination of serum ALT and AST
Serum samples were centrifuged in 2000  g for 20
min at 4C. Serum levels of ALT and AST were
determined by ELISA according to the manufactur-
er’s instructions (SunRed Biotechnology, Shanghai,
China) and were expressed as pictogram per millilitre
serum.
Determination of protein concentration
Using a commercial protein assay kit (Bio-Rad), ali-
quots (20 mL) of the diluted samples (15 or 25
with distilled water) were mixed with 980 mL of dis-
tilled water with 200 mL Bradford reagent added to
each sample. After mixing and following 10 min incu-
bation, the samples were assayed spectrophotometri-
cally at 595 nm. Protein level was expressed as
milligram protein per millilitre.
OPA purification
OPA was purified by a multistep high-performance
liquid chromatography (HPLC) purification process
after an ethyl acetate extraction of the culture super-
natant of Bipolaris oryzae SZMC 13003 strain
according to the description of Bencsik et al. (http://
www.mdpi.com/2072-6651/6/9/2857). Briefly, the
concentrated organic phase was first loaded onto an
ECO 15/450V3 K glass column (YMC, Germany)
filled with Kieselgel 60 (Merck, Hungary) using ethyl
acetate/hexane (5:5, V/V, 2 mL/min) as mobile phase,
and the OPA contained fractions were pooled and
injected onto a reverse-phase Serva ODS (10  450
mm, 5 mm) HPLC column with water/acetonitrile
(3:7, V/V, 3 mL/min) eluent system to achieve OPA
with the purity of up to 96%. During the purification
procedure, the identification, quantitation and purity
of OPA were tested by analytical HPLC measure-
ments at a wavelength of 230 nm.
Statistical analysis
All data are presented as means + standard error of
mean. Statistical difference between two groups was
analysed with the two-tailed Student’s t-test. p Values
less than 0.05 were considered significant.
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Results
Plasma IL-6 and TNF-a concentrations
The plasma level of IL-6 was increased after treatment
with OPA. The administration of 1.0 mg/kg of OPA led
to a significant increase compared to the vehicle con-
trol group (55.8 + 5.97 vs. 77.9 + 5.51 pg/mL
plasma, *p < 0.05). Data are presented in Figure 1.
Similarly to the IL-6 values, the TNF-a level reached
the highest concentration at 1mg/kgOPA and showed a
significant difference compared to the vehicle control
(5.59+ 0.55 vs. 7.41+ 0.57 pg/mL plasma, *p < 0.05)
and to 0.1 mg/kg OPA-treated (5.82 + 0.26 pg/mL
plasma, pþ < 0.05) groups. Data are shown in Figure 2.
Plasma MPO and HO enzyme activity
The increasing doses of OPA caused a dose-
dependent elevation in plasma MPO activity in each
group compared to the vehicle control animals (vehi-
cle control: 45.3 + 2.04 mU/mL plasma, *p < 0.05;
0.01 mg/kg OPA: 53.3+ 2.86 mU/mL plasma, *p <
0.05; 0.1 mg/kg OPA: 56.9 + 2.22 mU/mL plasma,
**p < 0.01 and 1.0 mg/kg OPA: 59.2+ 2.5 mU/mL
plasma, **p < 0.01). Data are shown in Figure 3.
After 24 h of treatment with 1.0 mg/kg OPA, we
observed a significant decrease in HO enzyme activ-
ity compared to the vehicle control group (74.1 +
9.03 vs. 48.3 + 1.77 nM bilirubin/h/mL plasma, *p
< 0.05). In addition, we also observed significant dif-
ferences between 1.0 mg/kg and lower dose OPA-
treated groups (0.1 mg/kg OPA: 55.8 + 1.42 nM
bilirubin/h/mL plasma, þp < 0.05 and 0.01 mg/kg
OPA: 63.4 nM bilirubin/h/mL plasma, aap < 0.01).
Data are shown in Figure 4.
Cardiac LV IL-6 and TNF-a concentrations
As shown in Figures 5 and 6, OPA treatment did not
cause significant changes in IL-6 and TNF-a concen-
trations in cardiac LV.
Cardiac LV MPO and HO activity
The results show that administration of OPA did not
produce changes in the activity of MPO and HO
enzymes in cardiac LV. Data are shown in Figures 7
and 8.
Figure 1. The concentrations of plasma IL-6 (expressed as
pg/mL plasma) after 24 h of treatment with 0.01, 0.1 and 1
mg/kg OPA. Data are means + SEM, n ¼ 5. Statistical
significance: *p < 0.05 relative to the vehicle control group.
OPA: ophiobolin A; IL-6: interleukin-6; SEM: standard error
of mean.
Figure 2. The plasma levels of TNF-a (expressed as pg/mL
plasma) in vehicle control and OPA-treated groups. Data
are means + SEM, n ¼ 6–9. Statistical significance: *p <
0.05 relative to the vehicle control group; þp < 0.05 a
significant difference between animals treated with 0.1 and
1 mg/kg OPA. TNF-a: tumour necrosis factor-alpha; OPA:
ophiobolin A; SEM: standard error of mean.
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Serum ALT and AST concentrations
No differences in serum ALT and AST concentrations
in response to increasing doses of OPA were observed
between vehicle control and OPA-treated animals.
Data are shown in Figures 9 and 10.
Discussion
Recently, much interest has been generated for a wide
range of compounds from microbial sources with
reports demonstrating their role in the modulation of
inflammatory responses. Among these, several micro-
bial metabolites show potent anti-inflammatory
action;16 some derivatives contribute to chronic
inflammation and inflammatory diseases.
The aim of our study was to clarify the effects of
OPA, a phytotoxic sesterterpenoid of fungal origin, on
the modulation of pro-inflammatory cytokines such as
IL-6 and TNF-a. Furthermore, its effect on the inflam-
matory biomarker MPO activity as well as on the
activation of HO was also investigated.
In the current investigation, OPA was shown to
promote the inflammatory processes. We demon-
strated that administrations of 1.0 mg/kg of OPA led
to significant increases in the plasma levels of IL-6.
Similarly to the IL-6, the TNF-a level reached the
highest concentration at 1 mg/kg OPA. All these
inflammatory cytokines play a critical role in control-
ling many inflammatory responses.17 In a previous
study, Nagashima et al. observed elevation of serum
IL-6 level in 24-h rubratoxin B-treated mouse model.18
Dugyala et al. found that TNF-a plays a role in the
mechanism of fumonisin B toxicity.19 Gene expression
of inflammatory cytokine leads to another stage of
the inflammatory cascade and facilitates the recruit-
ment of effector cells such as monocytes and neutro-
phils to the site of disturbance. Neutrophils create a
cytotoxic environment by releasing noxious chemicals.
MPO is a hemoprotein that is stored in azurophilic
granules of polymorphonuclear neutrophils and
macrophages. MPO catalyses the conversion of chlor-
ide and hydrogen peroxide to hypochlorite and is
secreted during inflammatory condition.20 The ele-
vated MPO concentrations of both plasma and tissue
have been used as a marker of polymorphonuclear leu-
kocytosis in sepsis and inflammation.21–23 Our results
show that a single treatment with increasing doses of
Figure 3. Changes in plasma MPO activity (expressed as
mU/mL plasma) after 24 h of OPA treatment. Data are
means + SEM, n ¼ 7–9. Statistical significance: *p < 0.05
and **p < 0.01 relative to the vehicle control group. MOP:
myeloperoxidase; OPA: ophiobolin A; SEM: standard error
of mean.
Figure 4. Effects of OPA treatment on plasma level of HO
activity (expressed as nM bilirubin/h/mL plasma) after 24 h.
Data are means+ SEM, n¼ 6–7. Statistical significance: *p <
0.05 relative to the vehicle control group; þp < 0.05 a sig-
nificant difference between animals treated with 0.1 and 1.0
mg/kg OPA; aap < 0.01 a significant difference between ani-
mals treated with 0.01 and 1.0 mg/kg OPA. OPA: ophiobolin
A; HO: heme oxygenase; SEM: standard error of mean.
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Figure 5. The concentrations of IL-6 (expressed as pg/mg
protein) in the cardiac LV after 24 h of treatment with 0.01,
0.1 and 1.0 mg/kg OPA. Data are means+ SEM, n ¼ 6–8.
LV: left ventricle; OPA: ophiobolin A; IL-6: interleukin-6;
SEM: standard error of mean.
Figure 6. The levels of TNF-a (expressed as pg/mg pro-
tein) in the cardiac LV of vehicle control and OPA-treated
animals. Data are means+ SEM, n¼ 6–8. OPA: ophiobolin
A; TNF-a: tumour necrosis factor-alpha; LV: left ventricle;
SEM: standard error of mean.
Figure 7. MPO activity (expressed as mU/mg protein) in
the cardiac LV of vehicle control and OPA-treated animals.
Data are means+ SEM, n ¼ 7–8. OPA: ophiobolin A; LV:
left ventricle; MPO: myeloperoxidase; SEM: standard error
of mean.
Figure 8. HO activity (expressed as nM bilirubin/h/mg
protein) in the cardiac LV of vehicle control and OPA-
treated animals. Data are means + SEM, n ¼ 7. OPA:
ophiobolin A; LV: left ventricle; HO: heme oxygenase; SEM:
standard error of mean.
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OPA caused a dose-dependent increase in the plasma.
The administration of 1 mg/kg OPA induced 75%
increase in the MPO activity. MPO is linked to both
inflammation and oxidative stress by catalysing the
formation of oxidizing agents.
It has been reported that HO plays a central role in
regulating the levels of intracellular heme by catalysing
the oxidative degradation of heme and by generating
CO, biliverdin and bilirubin.24 Three isoforms of HO
have been described: an inducible isoform, HO-1 and
two constitutively expressed isoforms, HO-2 and
HO-3. In animal and human studies, HO-1 may affect
many pathways and cytokines. During physiological
processes, HO activity plays a role in the inhibition
of apoptosis and oxidative processes, with significant
reductions in inflammatory events including produc-
tion of inflammatory cytokines. HO-1 and its products
such as CO, biliverdin/ bilirubin and free iron may
modulate inflammation.24 CO can downregulate the
production of pro-inflammatory cytokines (e.g. IL-1,
IL-6 and TNF-a). These effects were attributed to
alterations of mitogen-activated protein kinase
(MAPK) activities, including p38 MAPK and c-Jun
kinase.25,26 Furthermore, HO-1/CO activation downre-
gulates the inflammatory response by blocking the
release of NO from inducible nitrogen monoxide
synthase and expression of the granulocyte macro-
phage colony-stimulating factor from macrophages
and smooth muscle cells.27 Jung et al. reported that
CO can modulate the activation of the NLRP3 inflam-
masome, which regulates the production of pro-
inflammatory cytokines.28 Devey et al. demonstrated
that HO-1 inhibits the production of TNF-a and IL-6 in
the liver.29 In another model, Kapturczak et al. showed
that HO-1 deficiency leads to increased production of
pro-inflammatory cytokines.30 Our data indicate that
treatment with the fungal phytotoxin, OPA, increased
the concentrations of IL-6, TNF-a and MPO inflam-
matory mediators in blood plasma. The plasma HO
activity showed a significant reduction 24 h after
administrations of OPA. In agreement with previous
observations, our results show that systemic inflamma-
tion suppresses the level of HO.
Elevated circulating concentrations of pro-
inflammatory cytokines and adhesion molecules sug-
gest that inflammatory processes are occurring sys-
temically and play a role in the development of
inflammatory disorders, including allergic reactions,
arthritis, cancer, atherosclerosis and ischemic heart
disease.31,32 Although, many studies have detected a
positive correlation between inflammation and cardi-
ovascular diseases in different models, we did not
observe inflammation-related changes in cardiac tis-
sue after 24 h of acute OPA administrations. Animal
Figure 9. The concentrations of serum ALT (expressed as
mU/mL serum) in vehicle control and OPA-treated groups.
Data are means + SEM, n ¼ 11–12. ALT: alanine amino-
transferase;OPA:ophiobolinA; SEM: standarderrorofmean.
Figure 10. The levels of serum AST (expressed as mU/mL
serum) in vehicle control and OPA-treated groups. Data are
means+ SEM, n ¼ 5–12. AST: aspartate aminotransferase;
OPA: ophiobolin A; SEM: standard error of mean.
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studies on TNF-a and development of atherosclerosis
have produced mixed results. Inhibition of TNF-a in
apoE-deficient mice resulted in significant decrease
of atheromatous lesions33 in wild-type animals, it pro-
duced no improvements.34 In another inflammation-
related disease model, Bury et al. revealed that this
fungal metabolite, OPA, displays in vivo antitumor
activity in mammalian.35
Since we obtained that OPA treatment led to sys-
temic inflammatory changes measured in plasma, our
aim was to clarify if there is any potential toxic effect
of OPA on both liver and cardiac tissue. In addition to
inflammatory changes, we found a significant HO
activity reduction in plasma. The decrease in circulat-
ing HO enzyme activity promotes oxidative processes
which can trigger hepatic damage and modulate path-
ways that control normal biological functions.36,37
To analyse the potential hepatotoxic effects of
OPA, ALT and AST markers were also measured. It
has been demonstrated that a great number of toxins,
microbial metabolites and natural products could
cause liver damage. Transaminases are located in
liver cells and leak out into the circulation when liver
cells are injured. Ozer et al. reported that serum/
plasma ALT and AST biomarkers in humans and rats
have potential to be utilized as bridging markers to
monitor liver injury in early clinical trials. The ALT is
a more specific indicator of liver inflammation than
AST, which is also found in the heart and skeletal
muscle.38 Hepatic dysfunction accompanied by ele-
vated ALT and AST levels show a complex relation-
ship with cardiac diseases.39 In our study, we did not
observed changes in the serum ALT and AST concen-
trations after 24 h of treatment with 0.01, 0.1 and 1
mg/kg OPA.
In summary, the current report highlights the acute
role of OPA in systemic and cardiac-specific inflam-
matory responses. While the inflammation-inducing
effects mediated by OPA in the plasma seem related
to the activation of inflammatory markers (e.g. IL-6,
TNF-a and MPO) and the suppression of HO enzyme,
in the cardiac tissue, OPA treatment did not cause
changes in the inflammatory responses. Furthermore,
OPA did not show cytotoxic effects in the serum ALT
and AST levels.
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